Prediction of left ventricular thrombus after myocardial infarction: a cardiac magnetic resonance-based prospective registry.

Cardiac magnetic resonance Left ventricular ejection fraction Left ventricular thrombus Residual ST-segment elevation ST-segment elevation myocardial infarction Summatory of ST-segment elevation

Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 17 07 2024
revised: 28 08 2024
accepted: 18 09 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 9 10 2024
Statut: aheadofprint

Résumé

Left ventricular thrombus (LVTh) is a severe complication after ST-segment elevation myocardial infarction (STEMI). We aim to predict LVTh occurrence by cardiac magnetic resonance (CMR) using clinical, echocardiographic, and electrocardiographic (ECG) variables readily available at admission. We included 590 reperfused STEMI patients who underwent early (1-week) and/or late (6-month) CMR in our institution. Baseline clinical, echocardiographic (left ventricular ejection fraction -LVEF-) and ECG data (summatory of ST-segment elevation -sum-STE- and Q-wave and residual ST-elevation >1 mm -Q-STE-) during admission were registered. Multivariate binary logistic regression models and receiver operating characteristic curves were computed for LVTh prediction. LVTh was detected by CMR in 43 (7.3 %) patients and was predicted by previous chronic coronary syndrome (CCS, HR 4.74 [1.82-12.35], p = 0.001), anterior STEMI (HR 10.93 [2.47-48.31], p = 0.002), LVEF (HR 0.96 [0.93-0.99] per %, p = 0.008), maximum sum-STE (HR 1.04 [1.01-1.07] per mm, p = 0.04), and Q-STE (HR 1.31 [1.08-1.6] per lead, p = 0.008). High-risk patients with both major (anterior STEMI and Q-STE in ≥1 leads) and 1-3 minor (CCS, maximum sum-STE >10 mm, LVEF <50%) factors showed the highest LVTh risk (19.6 % within 6 months). The model showed excellent discrimination ability (area under the curve=0.85 [0.81-0.9], p < 0.001). Simplified 4-variable (excluding sum-STE) and 3-variable (also excluding CCS) risk scores showed similar discrimination ability and were externally validated. LVTh within 6 months post-STEMI can be predicted using pre-discharge clinical (anterior infarction and CCS), echocardiographic (LVEF), and ECG (sum-STE and Q-STE) data. Our results can help select patients who should undergo CMR after STEMI for LVTh detection.

Sections du résumé

BACKGROUND BACKGROUND
Left ventricular thrombus (LVTh) is a severe complication after ST-segment elevation myocardial infarction (STEMI).
OBJECTIVES OBJECTIVE
We aim to predict LVTh occurrence by cardiac magnetic resonance (CMR) using clinical, echocardiographic, and electrocardiographic (ECG) variables readily available at admission.
METHODS METHODS
We included 590 reperfused STEMI patients who underwent early (1-week) and/or late (6-month) CMR in our institution. Baseline clinical, echocardiographic (left ventricular ejection fraction -LVEF-) and ECG data (summatory of ST-segment elevation -sum-STE- and Q-wave and residual ST-elevation >1 mm -Q-STE-) during admission were registered. Multivariate binary logistic regression models and receiver operating characteristic curves were computed for LVTh prediction.
RESULTS RESULTS
LVTh was detected by CMR in 43 (7.3 %) patients and was predicted by previous chronic coronary syndrome (CCS, HR 4.74 [1.82-12.35], p = 0.001), anterior STEMI (HR 10.93 [2.47-48.31], p = 0.002), LVEF (HR 0.96 [0.93-0.99] per %, p = 0.008), maximum sum-STE (HR 1.04 [1.01-1.07] per mm, p = 0.04), and Q-STE (HR 1.31 [1.08-1.6] per lead, p = 0.008). High-risk patients with both major (anterior STEMI and Q-STE in ≥1 leads) and 1-3 minor (CCS, maximum sum-STE >10 mm, LVEF <50%) factors showed the highest LVTh risk (19.6 % within 6 months). The model showed excellent discrimination ability (area under the curve=0.85 [0.81-0.9], p < 0.001). Simplified 4-variable (excluding sum-STE) and 3-variable (also excluding CCS) risk scores showed similar discrimination ability and were externally validated.
CONCLUSIONS CONCLUSIONS
LVTh within 6 months post-STEMI can be predicted using pre-discharge clinical (anterior infarction and CCS), echocardiographic (LVEF), and ECG (sum-STE and Q-STE) data. Our results can help select patients who should undergo CMR after STEMI for LVTh detection.

Identifiants

pubmed: 39384454
pii: S0953-6205(24)00406-0
doi: 10.1016/j.ejim.2024.09.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest disclosures Julio Núñez reports personal fees from Alleviant, Bayer, Astra Zeneca, Novartis, Boehringer-Ingelheim, Rovi, and Novo Nordisk, not related to the contents of this paper. The other authors report no conflicts of interest.

Auteurs

Carlos Bertolin-Boronat (C)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain.

Víctor Marcos-Garcés (V)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.

Hector Merenciano-González (H)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.

Nerea Perez (N)

INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.

Candelas Pérez Del Villar (C)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Department of Cardiology, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Faculty of Medicine, University of Salamanca, Salamanca, Spain.

Jose Gavara (J)

INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Center for Biomaterials and Tissue Engineering, Universitat Politècnica de València, Valencia, Spain.

Maria P Lopez-Lereu (MP)

Cardiovascular Magnetic Resonance Unit, ASCIRES Biomedical Group, Valencia, Spain.

Jose V Monmeneu (JV)

Cardiovascular Magnetic Resonance Unit, ASCIRES Biomedical Group, Valencia, Spain.

Cristian Herrera Flores (C)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Department of Cardiology, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Blanca Domenech-Ximenos (B)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Cardiothoracic Imaging - Diagnostic Imaging Center, Hospital Clínic, Barcelona, Spain.

Francisco Jesús López-Fornás (FJ)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.

Cesar Rios-Navarro (C)

INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain.

Elena de Dios (E)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.

David Moratal (D)

Center for Biomaterials and Tissue Engineering, Universitat Politècnica de València, Valencia, Spain.

Jose T Ortiz-Pérez (JT)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Cardiovascular Institute, Hospital Clínic, Barcelona, Spain.

Antoni Bayes-Genis (A)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Cardiology Department and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.

Jose F Rodríguez-Palomares (JF)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Vall d'Hebron Institut de Recerca, Barcelona, Spain.

Julio Nuñez (J)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain.

Pedro L Sánchez (PL)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Department of Cardiology, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Faculty of Medicine, University of Salamanca, Salamanca, Spain.

Juan Sanchis (J)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain.

Vicente Bodi (V)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain; Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain. Electronic address: vicente.bodi@uv.es.

Classifications MeSH